---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-017520"
form_type: "8-K"
ticker: "ICCC"
cik: "0000811641"
company_name: "IMMUCELL CORP /DE/"
filed_at: "2024-02-27T23:59:59+00:00"
generated_at: "2026-06-05T13:39:15.970929+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# ImmuCell FY2023 net loss widens to $5.8M; Q4 sales up 30% but margin pressured

## Summary
- Net loss $5.8M ($0.75 per share) in FY2023 vs $2.5M ($0.32) prior year.
- Product sales $17.5M in FY2023, down 6% from $18.6M; Q4 sales $5.1M, up 30%.
- Gross margin fell to 22% in FY2023 from 41% due to contamination events and write-offs.
- EBITDA turned negative to ($2.6M) vs positive $350K in FY2022.
- Cash dropped to <$1M from $5.8M; FDA response on Re-Tain expected by May 2024.

## SEC filing metadata
- accession: 0001213900-24-017520
- form_type: 8-K
- ticker: ICCC
- cik: 0000811641
- company_name: IMMUCELL CORP /DE/
- filed_at: 2024-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/811641/000121390024017520/0001213900-24-017520-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/811641/000121390024017520/ea0200797-8k_immucell.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-017520
- JSON: https://secwatch.observer/filing/0001213900-24-017520.json
- Plain text: https://secwatch.observer/filing/0001213900-24-017520.txt

## Key facts
- Earnings Releases
  IMMUCELL CORP /DE/ reported the three-month period ended December 31, 2023 results: revenue $5.1 million, net income Net loss was $1.1 million, EPS $0.15 per basic share.
  - Period: the three-month period ended December 31, 2023
  - Revenue: $5.1 million
  - Net income: Net loss was $1.1 million
  - EPS: $0.15 per basic share
  - Result: reported results
  source text: Product sales increased by 30%, or $1.2 million, to $5.1 million during the three-month period ended December 31, 2023 compared to $3.9 million during the three-month period ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/811641/000121390024017520/0001213900-24-017520-index.htm
- Earnings Releases
  IMMUCELL CORP /DE/ reported financial results for the quarter and year ended December 31, 2023.
  - Period: the quarter and year ended December 31, 2023
  - Result: reported results
  source text: On February 27, 2024 ImmuCell Corporation (the "Company") issued a press release announcing its unaudited financial results for the quarter and year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/811641/000121390024017520/0001213900-24-017520-index.htm
- Earnings Releases
  IMMUCELL CORP /DE/ reported the year ended December 31, 2023 results: revenue $17.5 million, net income Net loss was $5.8 million, EPS $0.75 per basic share.
  - Period: the year ended December 31, 2023
  - Revenue: $17.5 million
  - Net income: Net loss was $5.8 million
  - EPS: $0.75 per basic share
  - Result: reported results
  source text: Product sales decreased by 6%, or $1.1 million, to $17.5 million during the year ended December 31, 2023 compared to $18.6 million during the year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/811641/000121390024017520/0001213900-24-017520-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.